Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.

Effect of Drug Clinical Trial

Official title:

Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05606796
• Other study ID #: Chinyei
• Status: Recruiting
• Phase: Phase 4
• Start date: December 2022
• Est. completion date: September 2023

Study information

• Verified date: November 2022
• Source: University of Lagos, Nigeria
• Contact: Uzoma C Joan, MBBS
• Phone: +2348033336844
• Email: chinyuzoma[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a randomised, double-blinded clinical trial in which consenting participants who meet the inclusion criteria would be randomised into 2 groups. Subjects will be given either preserved or preservative free latanoprost for a period of 12 weeks. The efficacy and tolerability of both drugs would be assessed every 4 weeks, amongst these patients.

Description:

Ethical approval has been obtained from the Health Research Ethics Committee of Lagos University Teaching Hospital.

Patients will be recruited from the weekly glaucoma clinic, Monday, Thursday, and Friday general clinics. Each participant would be seen for a period of 12 weeks; at baseline visit, and weeks 4, 8 and 12, in which topical, label-masked preserved or preservative free latanoprost would be dispensed, with patient instructed to instill one drop of 0.005% latanoprost by 9:00pm (± 1 hour). Efficacy of the two eye drops will be assessed by measuring the intraocular pressure 3 times a day at every visit. Safety and potential adverse effects of the drops will be evaluated in terms of ocular symptoms and tear parameters. Ocular symptom values of the patients will be evaluated.

All patients will undergo ocular examinations, including visual acuity assessment, slit lamp biomicroscopy, intraocular pressure, tear film breakup time (TBUT), fluorescein staining, schirmer test, gonioscopy, standard automated perimetry, and ophthalmoscopy. Tolerability will be evaluated with the frequency and percentage of distributions of severity level using the OSDI questionnaire in each group after administration at weeks 4 and 12, respectively. The symptoms checked during follow-up visits will include; pruritus, burning/stinging, blurred vision, tearing, sticky eye sensation, eye dryness sensation, and foreign body sensation. Quality of life would be evaluated at baseline visit and at week 12, using the standard quality of life Q-15 questionnaire.

A research team would be involved in carrying out this research, Comprising the principal researcher, a pharmacist, and 2 ophthalmic nurses. Results will be collated and analysed by the principal researcher. The entire research would be carried out over a period of 9 months, from December 2022 to August 2023.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: September 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 100 Years

Eligibility

Inclusion Criteria:

• Recently diagnosed, consenting high tension, primary open angle glaucoma or ocular hypertensive patients.

• Forty years and above.

• Intraocular pressure of 21- 30mmHg (millimetres of mercury)

• Willingness to participate in the study.

Exclusion Criteria:

• Patients under 40 years of age.

• Diabetic patients

• Patients on other anti- glaucoma medications.

• Patients on topical immunosuppressive medication.

• Patients on anti-depressants.

• Patients who have had any form of ocular surgery or intervention such as cryotherapy.

• Patients using contact lens.

• Patients on any form of topical medication in the last 1 month.

• Patients diagnosed or suspected to have Sjogren syndrome.

• Patients being managed for Steven-Johnson's syndrome, ocular cicatricial pemphigoid.

• Pregnant patients.

• Previous glaucoma surgery and any refractive surgery <12 month prior to enrolment.

• Only eye patients.

Related Conditions & MeSH terms

• Effect of Drug
• Glaucoma
• Glaucoma, Open-Angle

Intervention

Drug:
• Latanoprost 0.005% Ophthalmic Solution
1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.

Locations

Country	Name	City	State
Nigeria	Guinness Eye Centre. Lagos University Teaching Hospital.	Lagos	Lagos State

Sponsors (1)

Lead Sponsor	Collaborator
Uzoma Chinyei Joan

Country where clinical trial is conducted

Nigeria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intraocular pressure assessment.	Intraocular pressure measured in millimetre mercury (mmHg), will be assessed every 4 weeks at 8am,12pm and 4pm. Normal intraocular pressure ranges between 9 to 21mmHg. Any intraocular pressure values above 21mmHg would be considered abnormal. Pressures below 6mmHg will be considered as hypotony.	12 weeks
Secondary	Ocular surface disease index (OSDI) questionnaire.	The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patient's responses are rated on a scale of 0 to 4, with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated, which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.	4 weekly in 12 weeks.
Secondary	Quality of life-15 questionnaire.	Questionnaire is composed of 15 items, 4 domains which address factors of visual disability: central and near vision, peripheral vision, dark adaptation and glare, and outdoor mobility. Poorer QoL scores are associated with worse functional status and increased visual morbidity from glaucoma	Baseline visit and week 12.